Pearl Therapeutics Acquired For $1.15 Billion
Venture backed pharmaceuticals firm Pearl Therapeutics has been acquired by AstraZeneca in a deal worth up to $1.15 billion, the firms said today. Pearl Therappeutics is a developer of inhaled bronchodilator products for the treatment of patients with COPD. Pearl Therapeutics was venture backed by 5AM Ventures, Clarus Ventures, Nektar Therapeutics, New Leaf Venture Partners, and Vatera Holdings. AstraZenea said it will pay $560M for Pearl with up to $450M in earnout.
posted on Monday, June 10, 2013
Related companies:
Pearl App, LLC
Related stories:
> Pearl Therapeutics Raises $15.5M
> Pearl Therapeutics Gains $65M
> Pearl.com Gets $25.7M More
> Pearl Therapeutics Gets $69M
> Canaan Partners Raises $675M Fund
silicontap.com Home